AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8898512 — intervention group
Group type: COMPARATOR
Intervention: Direct measurement (DM) via standard open circuit spirometry
Number of subjects: 500
Study 1649874 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of two rotavirus vaccine strains (VP7 serotypes 1 and 2)
Number of subjects: 0
Study 6360401 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (1000 mg)
Number of subjects: 99
Study 6360401 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (1500 mg + 75 mg pyrimethamine)
Number of subjects: 99
Study 6360401 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 99
Study 6360401 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 99
Study 6360401 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 30893284 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Fastrach‐flexible bronchoscopy‐guided technique
Number of subjects: 40
Study 30893284 — intervention group
Group type: COMPARATOR
Intervention: Video laryngoscopy‐guided intubation
Number of subjects: 40
Study 29920594 — intervention group
Group type: COMPARATOR
Intervention: 0 μg/d vitamin D3
Number of subjects: 110
Study 29920594 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg/d vitamin D3
Number of subjects: 110
Study 29920594 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg/d vitamin D3
Number of subjects: 110
Study 27628763 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (low-dose, short-term use)
Number of subjects: 78615
Study 27628763 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (low-dose)
Number of subjects: 78615
Study 27628763 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (long-term, high-dose use)
Number of subjects: 78615
Study 27628763 — intervention group
Group type: COMPARATOR
Intervention: Other anticoagulants
Number of subjects: 78615
Study 24979398 — intervention group
Group type: EXPERIMENTAL
Intervention: AM‐111 0.4 mg/ml
Number of subjects: 210
Study 24979398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 22024564 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk product enriched with soy isoflavones (50 mg/day)
Number of subjects: 99
Study 22024564 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 99
Study 19901111 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (docetaxel/doxorubicin/cyclophosphamide (TAC) or two cycles of TAC followed by four cycles of vinorelbine/capecitabine)
Number of subjects: 2064
Study 19901111 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 2064
Study 17660130 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 92
Study 17660130 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Opiate Regimen (IOR)
Number of subjects: 92
Study 17660130 — intervention group
Group type: COMPARATOR
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 92
Study 16189745 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract WS(R) 5570/5572
Number of subjects: 594
Study 16189745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 12161224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational spin coronary angiography
Number of subjects: 15
Study 10433621 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid (13‐cis‐RA)
Number of subjects: 68
Study 10433621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 8535552 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10-20 mg daily
Number of subjects: 23
Study 8535552 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100-200 mg daily
Number of subjects: 23
Study 8535552 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of felodipine 10-20 mg plus metoprolol 100 mg daily
Number of subjects: 23
Study 8535552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2199180 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 I.U. calcitonin subcutaneously every second evening
Number of subjects: 59
Study 2199180 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 I.U. calcitonin subcutaneously every evening
Number of subjects: 59
Study 2199180 — intervention group
Group type: COMPARATOR
Intervention: No specific medication
Number of subjects: 59
Study 872364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridine-extracted alum-precipitated grass pollen vaccine (Alavac P)
Number of subjects: 19
Study 872364 — intervention group
Group type: COMPARATOR
Intervention: Glutaraldehyde-modified pollen-tyrosine vaccine (Pollinex)
Number of subjects: 19
Study 31752802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis treatment
Number of subjects: 320
Study 31752802 — intervention group
Group type: EXPERIMENTAL
Intervention: Current alcohol consumption
Number of subjects: 320
Study 31752802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco product use, current alcohol consumption, family history of diabetes, and stress level
Number of subjects: 320
Study 28506378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention (contacting primary care prescribers by phone and fax to obtain a prescription for an appropriate statin)
Number of subjects: 420
Study 28506378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 420
Study 28506378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 420
Study 28506378 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 420
Study 24335848 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan 16 mg
Number of subjects: 72
Study 24335848 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 160 mg
Number of subjects: 72
Study 24335848 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 23511692 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g acetaminophen
Number of subjects: 53
Study 23511692 — intervention group
Group type: COMPARATOR
Intervention: 1 g dextrose (placebo)
Number of subjects: 53
Study 20847992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosci technique
Number of subjects: 15
Study 20847992 — intervention group
Group type: COMPARATOR
Intervention: Summers technique
Number of subjects: 15
Study 19075138 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel, 5%
Number of subjects: 64
Study 19075138 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 64
Study 19075138 — intervention group
Group type: COMPARATOR
Intervention: Dapsone gel, 5% and Vehicle gel
Number of subjects: 64
Study 16550976 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tramadol
Number of subjects: 44
Study 16550976 — intervention group
Group type: COMPARATOR
Intervention: IV lornoxicam
Number of subjects: 44
Study 14599636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for severe combined immunodeficiency disorder
Number of subjects: 0
Study 14599636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for cystic fibrosis
Number of subjects: 0
Study 14599636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for coronary artery disease
Number of subjects: 0
Study 14599636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for peripheral arterial disease
Number of subjects: 0
Study 14599636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for hemophilia
Number of subjects: 0
Study 14599636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (general)
Number of subjects: 0
Study 10920683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Support Team (NST)
Number of subjects: 96
Study 10920683 — intervention group
Group type: COMPARATOR
Intervention: Non-NST
Number of subjects: 96
Study 9188878 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (3 micrograms/g) ointment
Number of subjects: 24
Study 9188878 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 micrograms/g) ointment
Number of subjects: 24
Study 7925201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (3 x ED90)
Number of subjects: 0
Study 7925201 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (3 x ED90)
Number of subjects: 0
Study 3194074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 1 g intravenously at induction of anaesthesia
Number of subjects: 240
Study 3194074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g intravenously at induction of anaesthesia
Number of subjects: 240
Study 31438861 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposcope endoscope-guided NTI
Number of subjects: 60
Study 31438861 — intervention group
Group type: COMPARATOR
Intervention: Fibreoptic bronchoscopy-guided NTI
Number of subjects: 60
Study 31438861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 28099359 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon-enhanced CT using a single-breath-hold technique
Number of subjects: 26
Study 27738739 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized perioperative behavioral/pelvic floor exercise intervention plus midurethral sling
Number of subjects: 210
Study 27738739 — intervention group
Group type: COMPARATOR
Intervention: Midurethral sling alone
Number of subjects: 210
Study 24206459 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (20 mg daily)
Number of subjects: 2185
Study 24206459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study 21889878 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg once daily
Number of subjects: 301
Study 21889878 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 80 mg BID
Number of subjects: 301
Study 18927168 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) group
Number of subjects: 35
Study 18927168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET) group
Number of subjects: 35
Study 18927168 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 17926618 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye acupuncture
Number of subjects: 180
Study 17926618 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 180
Study 17926618 — intervention group
Group type: COMPARATOR
Intervention: Bucinnazine
Number of subjects: 180
Study 15521869 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial polyps
Number of subjects: 78
Study 15521869 — intervention group
Group type: COMPARATOR
Intervention: Normal endometrium
Number of subjects: 78
Study 11172164 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 or 5.0 mg daily)
Number of subjects: 9331
Study 11172164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9331
Study 8968227 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic adrenalectomy (TLPA)
Number of subjects: 9
Study 8968227 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic approach (RLPA)
Number of subjects: 9
Study 1610635 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia with enflurane in nitrous oxide with spontaneous ventilation
Number of subjects: 40
Study 1610635 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia with isoflurane in nitrous oxide with spontaneous ventilation
Number of subjects: 40
Study 1610635 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia with enflurane in nitrous oxide with controlled ventilation
Number of subjects: 40
Study 1610635 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia with isoflurane in nitrous oxide with controlled ventilation
Number of subjects: 40
Study 3918510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan in combination with chemotherapeutic agents (5FU + mitomycin C or tegafur)
Number of subjects: 0
Study 3918510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan in combination with tegafur for gastric cancer
Number of subjects: 0
Study 3918510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan in combination with tegafur for colorectal cancer
Number of subjects: 0
Study 30866888 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT biscuits and nutrition education
Number of subjects: 0
Study 30866888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education only
Number of subjects: 0
Study 30866888 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT biscuits only
Number of subjects: 0
Study 30062572 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention (n=93)
Number of subjects: 151
Study 30062572 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=58)
Number of subjects: 151
Study 30062572 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention (n=93) among women with stage 0/I
Number of subjects: 151
Study 30062572 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=58) among women with stage 0/I
Number of subjects: 151
Study 30062572 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention in women with stage II/III
Number of subjects: 151
Study 27684867 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneously removable biliary stent drainage
Number of subjects: 47
Study 27684867 — intervention group
Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 47
Study 24650858 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 100
Study 24650858 — intervention group
Group type: COMPARATOR
Intervention: Fibromyalgia Education (FE)
Number of subjects: 100
Study 22429658 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific echocardiographic criteria for diastolic LV dysfunction
Number of subjects: 1258
Study 22429658 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic dysfunction groups 1 (impaired relaxation), 2 (possible elevated LV filling pressure), and 3 (elevated E/e' and abnormally low E/A)
Number of subjects: 1258
Study 19443680 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin 10 mg/kg + Aztreonam 2 g
Number of subjects: 23
Study 19443680 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin 10 mg/kg + Piperacillin/Tazobactam 4.5 g
Number of subjects: 23
Study 19443680 — intervention group
Group type: COMPARATOR
Intervention: Telavancin 10 mg/kg
Number of subjects: 23
Study 19443680 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam 2 g
Number of subjects: 23
Study 19443680 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/Tazobactam 4.5 g
Number of subjects: 23
Study 17877851 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality measures (authoritarianism, personal need for structure, ethnocentrism, social dominance orientation)
Number of subjects: 0
Study 17877851 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group identification
Number of subjects: 0
Study 17877851 — intervention group
Group type: EXPERIMENTAL
Intervention: Social dominance orientation (SDO)
Number of subjects: 0
Study 15051633 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 70
Study 15051633 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/d)
Number of subjects: 70
Study 15051633 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 70
Study 15051633 — intervention group
Group type: COMPARATOR
Intervention: Unstable angina patients
Number of subjects: 70
Study 15051633 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 70
Study 11270009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5 L min‐1 for at least 2 h)
Number of subjects: 76
Study 11270009 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.5 L min‐1 for at least 2 h)
Number of subjects: 76
Study 9698963 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (propofol and remifentanil)
Number of subjects: 50
Study 9698963 — intervention group
Group type: COMPARATOR
Intervention: DN (desflurane-N2O)
Number of subjects: 50
Study 10512080 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg/day
Number of subjects: 250
Study 10512080 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 25-75 mg/day
Number of subjects: 250
Study 2376155 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP, 500 micrograms twice daily)
Number of subjects: 16
Study 2376155 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 16
Study 216235 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oxazepam
Number of subjects: 2
Study 216235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31418140 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg daily for 48 weeks
Number of subjects: 188
Study 31418140 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 188
Study 27899322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin and/or sulbactam administered 1 hour before ESD and every 8 hours twice more (group 1)
Number of subjects: 100
Study 27899322 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution without antibiotics (group 2)
Number of subjects: 100
Study 26414759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) plus usual care (UC)
Number of subjects: 158
Study 26414759 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 158
Study 23642010 — intervention group
Group type: EXPERIMENTAL
Intervention: Web 1.0 intervention (access to an existing physical activity website with limited interactivity)
Number of subjects: 504
Study 23642010 — intervention group
Group type: EXPERIMENTAL
Intervention: Web 2.0 intervention (access to a website featuring Web 2.0 content, including social networking, blogs, and virtual walking groups)
Number of subjects: 504
Study 23642010 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a logbook to record their steps)
Number of subjects: 504
Study 23642010 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including Web 1.0, Web 2.0, and Control)
Number of subjects: 504
Study 21315749 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activation following threatening stimuli in the left temporo‐parietal junction and right extrastriate body area correlating with more social inhibition traits.
Number of subjects: 26
Study 21315749 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative correlation between negative affectivity and activation of the amygdala, fusiform gyrus, insula, and hippocampus.
Number of subjects: 26
Study 21315749 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive correlation with social inhibition in the orbitofrontal cortex, superior temporal sulcus, inferior frontal gyrus (Brodmann area 45), and temporal pole.
Number of subjects: 26
Study 19826188 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechins (GTC) - 670 mg per day (6 capsules)
Number of subjects: 17
Study 19826188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 19826188 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary GTC (5 g GTC/kg) in male rats
Number of subjects: 17
Study 19826188 — intervention group
Group type: COMPARATOR
Intervention: Lower dietary GTC (0, 0.05, 0.5, 1 g GTC/kg) in male rats
Number of subjects: 17
Study 16962480 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563
Number of subjects: 40
Study 16962480 — intervention group
Group type: COMPARATOR
Intervention: ATG
Number of subjects: 40
Study 15458566 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mls of nebulized isotonic saline using an efficient nebulizer (active group n = 20)
Number of subjects: 40
Study 15458566 — intervention group
Group type: COMPARATOR
Intervention: 4 mls of nebulized saline using an inefficient nebulizer (placebo group n = 20)
Number of subjects: 40
Study 11372037 — intervention group
Group type: EXPERIMENTAL
Intervention: TFPI (0.2 mg/kg/h after a bolus of 0.05 mg/kg)
Number of subjects: 8
Study 11372037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9236484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (0.5, 1, or 2 g/kg)
Number of subjects: 99
Study 9236484 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (1% albumin)
Number of subjects: 99
Study 8106652 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 219
Study 8106652 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 219
Study 8106652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 3308970 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice containing zinc citrate and Triclosan for 6 months
Number of subjects: 101
Study 3308970 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice for 6 months
Number of subjects: 101
Study 29874180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted ETP
Number of subjects: 195458
Study 29874180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted vWF
Number of subjects: 195458
Study 29874180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted FVIII
Number of subjects: 195458
Study 29874180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted d‐dimer
Number of subjects: 195458
Study 29874180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted tPA
Number of subjects: 195458
Study 29874180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted PAI-1
Number of subjects: 195458
Study 28611206 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation (CPVI) alone (n=59)
Number of subjects: 113
Study 28611206 — intervention group
Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (CPVI) plus linear ablation (CPVI+Line; n=54)
Number of subjects: 113
Study 26111066 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT (n = 131)
Number of subjects: 257
Study 26111066 — intervention group
Group type: COMPARATOR
Intervention: TAU (n = 126)
Number of subjects: 257